In clinical trials, durability of response is measured using criteria such as Progression-Free Survival (PFS) and Overall Survival (OS). These metrics help researchers understand how long a treatment can keep cancer from advancing. The RECIST criteria are often used to standardize assessments of tumor response, providing a framework for comparing the effectiveness of different treatments.
